HRSA-22-082: Sudden Unexpected Infant Death Prevention
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants of up to $500,000 to the applicants described in the notice. It expected to make one award worth $500,000 in total. Applications closed on February 3, 2022.
From the official notice on Grants.gov, last changed November 5, 2021. Checked November 7, 2026.
- Award ceiling$500,000
- Total funding$500,000
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 5, 2021 |
|---|---|
| Deadline | February 3, 2022 |
| Archived by Grants.gov | April 4, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include any domestic public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C.§ 450b). See 42 CFR § 51a.3(a). Domestic faith-based and community-based organizations are also eligible to apply.
Is this a realistic fit?
- Past Special Projects of Regional and National Significance awards averaged $1.6 million; this notice allows up to $500,000 per award.
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Sudden Unexpected Infant Death (SUID) Prevention Program. The purpose of the SUID Prevention Program is to reduce overall rates of SUID and reduce racial and ethnic disparities in SUID by supporting pediatric health care practitioners to provide evidence-based counseling and education to infant caregivers and families; to guide system improvements; and to identify and support policy changes that address state- and community- specific SUID risks. For more details, see Program Expectations. The goals of the SUID Prevention Program are to: • Identify and promote state and community best practices in safe infant sleep and SUID prevention through a national coalition with broad representation of pediatric providers, social service providers, fatality review leaders, community organizations that represent those at highest risk for SUID, and families who have experienced a SUID; • Increase pediatric providers’ awareness, understanding, and use of fetal/infant mortality review (FIMR) and child death review (CDR) team data, findings, and recommendations that describe state- and community-specific causes of SUID and how these relate to infant caregiver/family practices, health and social services systems, and local policies; and • Engage pediatric providers in assisting infant caregivers/families to create a safe sleep environment through assessments for SUID risk and protective factors, counseling and education, working as a member of a FIMR or CDR team and associated community action teams and advisory boards to address social service system improvements, and initiate local policy changes to better address community-specific SUID risks. In order to achieve the goals, the recipient should meet the following objectives: • Within 3 months of the project launch, convene and lead a national coalition that engages nationally recognized organizations with expertise in SUID, safe infant sleep practices, breastfeeding, maternal health, fatality reviews, and culturally responsive infant caregiver/family communication.
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-082 still open?
No. It closed on February 3, 2022. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for Sudden Unexpected Infant Death Prevention?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Sudden Unexpected Infant Death Prevention?
Closed February 3, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each. About $500,000 in total for one award.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)